Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Cellular Injury IlI: Cellular Death01:11

Cellular Injury IlI: Cellular Death

Cell death is the irreversible loss of cellular structure and function, representing the final stage of severe injury. It plays a key role in both normal physiology and disease.Types of Cell DeathThe two main types are necrosis and apoptosis, though others like necroptosis and pyroptosis also exist.Necrosis:Necrosis is an unregulated form of cell death caused by severe injury such as trauma, toxins, or ischemia. It is characterized by cell swelling, membrane loss, rupture, and leakage of...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Cellular Injury IV: Necrosis01:16

Cellular Injury IV: Necrosis

Necrosis is a form of irreversible cell death caused by severe injury such as ischemia, toxins, or trauma. Unlike programmed cell death, it is an uncontrolled, pathological process that typically provokes inflammation in surrounding tissues.Pathophysiologic ChangesNecrosis begins when cells sustain critical damage, leading to swelling of organelles, particularly mitochondria, and rapid ATP depletion. As energy levels decline, membrane ion pumps fail, leading to calcium influx and eventually,...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.

Metabolomics : Official journal of the Metabolomic Society·2021
Same author

Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.

Metabolomics : Official journal of the Metabolomic Society·2020
Same author

Leukaemia: 'Gimme shelter'.

Nature reviews. Cancer·2017
Same author

Tumour metabolism: RED(D1) or dead.

Nature reviews. Cancer·2016
Same author

Tumour suppressors: Turning a negative into a positive.

Nature reviews. Cancer·2016
Same author

Evolution: Mix and re-match.

Nature reviews. Genetics·2015
Same journal

Escaping the trap.

Nature reviews. Cancer·2026
Same journal

A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.

Nature reviews. Cancer·2026
Same journal

Systemic health impact of cancer-associated extracellular vesicles and particles.

Nature reviews. Cancer·2026
Same journal

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026
Same journal

CLIM-TIME links tumour genetics to spatial immune architecture.

Nature reviews. Cancer·2026
Same journal

Serving sulfur to boost anti-tumour immunity.

Nature reviews. Cancer·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death
10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

Cell death. 1+1≠2.

Nicola McCarthy

    Nature Reviews. Cancer
    |June 15, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Pretreating triple-negative breast cancer cells with a targeted drug can enhance their sensitivity to chemotherapy. This approach may improve treatment efficacy for this aggressive cancer subtype.

    More Related Videos

    LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation
    06:12

    LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation

    Published on: May 3, 2024

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
    15:53

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

    Published on: August 21, 2013

    Related Experiment Videos

    Last Updated: May 21, 2026

    Evaluation of Caspase Activation to Assess Innate Immune Cell Death
    10:23

    Evaluation of Caspase Activation to Assess Innate Immune Cell Death

    Published on: January 20, 2023

    LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation
    06:12

    LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation

    Published on: May 3, 2024

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
    15:53

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

    Published on: August 21, 2013

    Area of Science:

    • Oncology
    • Pharmacology
    • Cancer Biology

    Background:

    • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to limited targeted therapy options.
    • Standard chemotherapy remains a cornerstone of TNBC treatment, but resistance often develops.
    • Identifying strategies to overcome chemoresistance is crucial for improving patient outcomes.

    Discussion:

    • This study investigates the potential of neoadjuvant targeted therapy to sensitize TNBC cells to conventional chemotherapy.
    • Researchers explored the effects of a specific targeted agent administered prior to chemotherapy initiation.
    • The findings suggest a synergistic interaction between targeted pretreatment and subsequent chemotherapy.

    Key Insights:

    • Pretreatment with a targeted drug significantly increased the sensitivity of triple-negative breast cancer cells to standard chemotherapy.
    • This enhanced sensitivity was observed after a defined period of targeted drug administration.
    • The results highlight a promising strategy for overcoming chemotherapy resistance in TNBC.

    Outlook:

    • This approach could lead to novel therapeutic strategies for managing triple-negative breast cancer.
    • Further clinical investigation is warranted to evaluate the efficacy and safety of this combined treatment modality.
    • Future research may focus on optimizing drug combinations and treatment schedules for personalized TNBC therapy.